What is HC Wainwright’s Estimate for NRXP FY2026 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Investment analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of NRx Pharmaceuticals in a note issued to investors on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $0.13 per share for the year, up from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $1.23 EPS, FY2028 earnings at $3.18 EPS and FY2029 earnings at $5.06 EPS.

A number of other research firms have also weighed in on NRXP. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Finally, Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Stock Performance

NRXP stock opened at $1.77 on Thursday. The business has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $2.50. The company has a market capitalization of $56.41 million, a P/E ratio of -0.75 and a beta of 1.97. NRx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $3.84.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. One Wealth Management Investment & Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 35.3% during the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after buying an additional 9,882 shares during the last quarter. State Street Corp grew its position in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after acquiring an additional 10,700 shares during the period. Ethos Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $39,000. Sjbenen Advisory LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $41,000. Finally, Two Sigma Investments LP raised its holdings in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Institutional investors own 4.27% of the company’s stock.

Key Headlines Impacting NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year EPS forecasts and reiterated a Buy rating with a $45 price target, projecting material earnings growth from FY2026 through FY2029 (Q4‑2026: $0.06; FY2026: $0.13; FY2027: $1.23; FY2028: $3.18; FY2029: $5.06). This signals that at least one boutique analyst expects a strong recovery and significant upside vs. the current share price. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock
• Neutral Sentiment: Zacks Research moved NRXP from “strong sell” to “hold,” reducing one source of bearish pressure but not endorsing a buy — a modest signal that downside may be stabilizing but not yet reversed. Zacks upgrade coverage (TickerReport)
• Negative Sentiment: HC Wainwright trimmed its Q3‑2026 EPS estimate (from $0.04 to $0.03), a near-term downgrade that tempers some of the upbeat multi-year outlook and highlights potential short-term execution or timing risk. MarketBeat NRXP coverage (analyst notes)
• Negative Sentiment: Consensus still shows a current full-year loss (consensus ~($1.75) EPS), so HC Wainwright’s optimistic projections are aggressive and depend on successful product/commercial execution and milestone delivery; failure to meet milestones would keep downside risk elevated. MarketBeat NRXP consensus data

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.